427 related articles for article (PubMed ID: 26049133)
1. Nanoengineering of vaccines using natural polysaccharides.
Cordeiro AS; Alonso MJ; de la Fuente M
Biotechnol Adv; 2015 Nov; 33(6 Pt 3):1279-93. PubMed ID: 26049133
[TBL] [Abstract][Full Text] [Related]
2. Polysaccharides as vaccine adjuvants.
Sun B; Yu S; Zhao D; Guo S; Wang X; Zhao K
Vaccine; 2018 Aug; 36(35):5226-5234. PubMed ID: 30057282
[TBL] [Abstract][Full Text] [Related]
3. Carbohydrate-containing nanoparticles as vaccine adjuvants.
Zhang X; Zhang Z; Xia N; Zhao Q
Expert Rev Vaccines; 2021 Jul; 20(7):797-810. PubMed ID: 34101528
[No Abstract] [Full Text] [Related]
4. Modified chitosan-based nanoadjuvants enhance immunogenicity of protein antigens after mucosal vaccination.
Sinani G; Sessevmez M; Gök MK; Özgümüş S; Alpar HO; Cevher E
Int J Pharm; 2019 Oct; 569():118592. PubMed ID: 31386881
[TBL] [Abstract][Full Text] [Related]
5. Controlled delivery of antigens and adjuvants in vaccine development.
Zhao Z; Leong KW
J Pharm Sci; 1996 Dec; 85(12):1261-70. PubMed ID: 8961136
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in vaccine adjuvants for systemic and mucosal administration.
O'Hagan DT
J Pharm Pharmacol; 1998 Jan; 50(1):1-10. PubMed ID: 9504429
[TBL] [Abstract][Full Text] [Related]
7. Nanovaccines : nanocarriers for antigen delivery.
Gonzalez-Aramundiz JV; Cordeiro AS; Csaba N; de la Fuente M; Alonso MJ
Biol Aujourdhui; 2012; 206(4):249-61. PubMed ID: 23419252
[TBL] [Abstract][Full Text] [Related]
8. Microparticles as vaccine adjuvants and delivery systems.
O'Hagan DT; Singh M
Expert Rev Vaccines; 2003 Apr; 2(2):269-83. PubMed ID: 12899577
[TBL] [Abstract][Full Text] [Related]
9. Chitosan-based mucosal adjuvants: Sunrise on the ocean.
Xia Y; Fan Q; Hao D; Wu J; Ma G; Su Z
Vaccine; 2015 Nov; 33(44):5997-6010. PubMed ID: 26271831
[TBL] [Abstract][Full Text] [Related]
10. Chitosan-based Nanoparticles in Mucosal Vaccine Delivery.
Mehrabi M; Montazeri H; Mohamadpour Dounighi N; Rashti A; Vakili-Ghartavol R
Arch Razi Inst; 2018 Sep; 73(3):165-176. PubMed ID: 30280836
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis.
de Jesus Pereira NC; Régis WC; Costa LE; de Oliveira JS; da Silva AG; Martins VT; Duarte MC; de Souza JR; Lage PS; Schneider MS; Melo MN; Soto M; Soares SA; Tavares CA; Chávez-Fumagalli MA; Coelho EA
Exp Parasitol; 2015 Jun; 153():180-90. PubMed ID: 25845753
[TBL] [Abstract][Full Text] [Related]
12. Cationic polymer modified PLGA nanoparticles encapsulating Alhagi honey polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses.
Wusiman A; Gu P; Liu Z; Xu S; Zhang Y; Hu Y; Liu J; Wang D; Huang X
Int J Nanomedicine; 2019; 14():3221-3234. PubMed ID: 31123399
[No Abstract] [Full Text] [Related]
13. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.
Vajdy M; Srivastava I; Polo J; Donnelly J; O'Hagan D; Singh M
Immunol Cell Biol; 2004 Dec; 82(6):617-27. PubMed ID: 15550120
[TBL] [Abstract][Full Text] [Related]
14. Novel application of trimethyl chitosan as an adjuvant in vaccine delivery.
Malik A; Gupta M; Gupta V; Gogoi H; Bhatnagar R
Int J Nanomedicine; 2018; 13():7959-7970. PubMed ID: 30538470
[TBL] [Abstract][Full Text] [Related]
15. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
[TBL] [Abstract][Full Text] [Related]
16. Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery.
Gause KT; Wheatley AK; Cui J; Yan Y; Kent SJ; Caruso F
ACS Nano; 2017 Jan; 11(1):54-68. PubMed ID: 28075558
[TBL] [Abstract][Full Text] [Related]
17. Harnessing self-assembled peptide nanoparticles in epitope vaccine design.
Negahdaripour M; Golkar N; Hajighahramani N; Kianpour S; Nezafat N; Ghasemi Y
Biotechnol Adv; 2017 Sep; 35(5):575-596. PubMed ID: 28522213
[TBL] [Abstract][Full Text] [Related]
18. Polymeric nanostructure vaccines: applications and challenges.
Simón-Vázquez R; Peleteiro M; González-Fernández Á
Expert Opin Drug Deliv; 2020 Jul; 17(7):1007-1023. PubMed ID: 32476491
[TBL] [Abstract][Full Text] [Related]
19. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
Hafner AM; Corthésy B; Merkle HP
Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in adjuvants for vaccines against infectious diseases.
O'Hagan DT; MacKichan ML; Singh M
Biomol Eng; 2001 Oct; 18(3):69-85. PubMed ID: 11566599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
